TD Cowen raised the firm’s price target on Neurocrine (NBIX) to $200 from $175 and keeps a Buy rating on the shares. The firm believes there is much growth left in Ingrezza, and expect rapid adoption for Crenessity in CAH. Neurocrine is one of the few high-growth, diversified, and profitable mid-cap biotech companies and expect it to be a top performer as Ingrezza’s revenue continues to increase, Crenessity’s launch progresses, and its pipeline advances.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
- Neurocrine Extends Eiry W. Roberts’ Employment Term
- Neurocrine’s Promising Prospects: Buy Rating Backed by Osavampator’s Success and Ingrezza’s Revenue Growth
- Neurocrine price target lowered to $173 from $178 at Morgan Stanley
- Neurocrine’s Growth Potential and Positive Outlook Justify Buy Rating Despite Setbacks